Biomoneta, an ISO 13485:2016 accredited innovation company, has secured $500,000 in a recent funding round from investors. This capital infusion marks a significant step for the company as it continues to develop and deploy its advanced air sterilization solutions. The investment underscores growing confidence in Biomoneta's proprietary technology and its potential to address critical public health challenges.
Biomoneta specializes in creating solutions for air sterilization based on its globally patented ZeBox Technology. ZeBox-powered air sterilizers are designed to efficiently isolate, trap, and kill a broad range of pathogens from free-flowing air. This is achieved through a combination of nanomaterials and power electronics, offering a robust defense against airborne contaminants. The company's focus on preventing the spread of infection gained particular relevance during the Covid-19 pandemic, highlighting the importance of effective air purification where no cure exists for certain pathogens.
The funding round is significant for Biomoneta as it aims to scale its operations and expand the reach of its ZeBox technology. The company plans to use the newly raised capital to accelerate research and development efforts, enhance manufacturing capabilities, and support market expansion initiatives. This investment will enable Biomoneta to further refine its existing products and explore new applications for its air sterilization platform.
Deployment of ZeBox-powered air sterilizers in controlled environments such as hospitals, clinics, labs, homes, and offices has the potential to arrest the spread of a range of infections, save lives, and prevent pandemics. With this new funding, Biomoneta is positioned to broaden the availability of its technology, aiming to make a substantial impact on public health and safety. The company anticipates continued growth as it works towards its mission of providing advanced solutions for cleaner, safer air globally.
